Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $54.4 million.

  • CG Oncology's Cash from Financing Activities rose 240899.86% to $54.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $277.9 million, marking a year-over-year decrease of 3085.59%. This contributed to the annual value of $628.3 million for FY2024, which is 62218.47% up from last year.
  • As of Q3 2025, CG Oncology's Cash from Financing Activities stood at $54.4 million, which was up 240899.86% from -$296000.0 recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Cash from Financing Activities ranged from a high of $402.7 million in Q1 2024 and a low of -$15.2 million during Q2 2023
  • In the last 3 years, CG Oncology's Cash from Financing Activities had a median value of $450000.0 in 2025 and averaged $70.0 million.
  • As far as peak fluctuations go, CG Oncology's Cash from Financing Activities surged by 5273503.27% in 2024, and later tumbled by 84000.0% in 2025.
  • Over the past 3 years, CG Oncology's Cash from Financing Activities (Quarter) stood at -$2.9 million in 2023, then skyrocketed by 7814.57% to $223.4 million in 2024, then crashed by 75.66% to $54.4 million in 2025.
  • Its Cash from Financing Activities stands at $54.4 million for Q3 2025, versus -$296000.0 for Q2 2025 and $450000.0 for Q1 2025.